All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on, How and when to treat patients with refractory or progressive Waldenstrom's macroglobulinemia (WM)? This discussion also featured Christian Buske, Monique Minnema, Sheeba Koshy Thomas, and Jorge J. Castillo.
How and when to treat patients with refractory or progressive WM
Minnema begins by discussing why treatment should only be restarted after measuring each individual patient’s IgM level, a vital indicator of disease progression. Both Minnema and Thomas place importance on the return of symptoms being a useful gauge to assess whether treatment should be restarted. Castillo remarks that readministering a prior regimen is a viable approach only if patients achieve durable responses and treatment is tolerated; however, in cases of relapsed disease, treatment with a different mechanism of action is often the next step. For example, treatment with chemoimmunotherapy and Bruton’s tyrosine kinase (BTK) inhibitors could be used as first and second-line treatments, respectively. Castillo also highlights BTK inhibitors as good follow-up therapy options. Finally, Buske covers novel treatment options following progression on ibrutinib, including the use of a non-covalent BTK inhibitors such as pirtobrutinib, immunochemotherapy, or venetoclax.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
What are the novel treatment options for patients with relapsed or refractory WM?
On behalf of the IWMF, the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on novel treatment options for...
Treatment landscape for R/R Waldenstrom's macroglobulinemia
Here, we summarize the treatment strategies in relapsed/refractory Waldenstrom's macroglobulinemia and highlight important factors influencing treatment choices in this setting.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox